Akebia raises another $41m for oral anemia drug
This article was originally published in Scrip
Akebia Theraputics has raised $41m in a series C financing round to fund on-going development of its lead compound, the oral anemia pill AKB-6548, taking the drug into Phase IIb testing in patients with anemia associated with chronic kidney disease (CKD).
You may also be interested in...
In an exclusive interview, Barbara Lueckel, global head of research technologies at Roche Pharma Partnering, talks about the rationale behind the 2020 deals with Bicycle Therapeutics and Nimble Therapeutics. She gives insight into how deal makers are shifting gears to make deals happen in the challenging environment of the global coronavirus pandemic.
As the COVID-19 pandemic escalates, companies across the world are preparing to roll out commercial test kits for the detection of SARS-CoV-2.
Biopharmaceutical companies doubled-down on rare disease treatments during the last five years, thanks to a potent combination of scientific discovery and appealing business incentives.